Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bicycle Therapeutics Plc ADR
(NQ:
BCYC
)
21.36
-0.82 (-3.70%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bicycle Therapeutics Plc ADR
< Previous
1
2
3
Next >
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
November 04, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal for ImmunoTherapy of Cancer
November 02, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration
October 26, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 18, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Pricing of Upsized Public Offering of $175 Million of American Depositary Shares
October 13, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Proposed $125,000,000 Public Offering of American Depositary Shares
October 12, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial
October 07, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Present BT5528 Interim Phase I Data at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
September 01, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Enters Exclusive License and Collaboration Agreement with Ionis to Develop Targeted Oligonucleotide Therapeutics
July 13, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Restrictions on Shareholder Attendance at Annual General Meeting to be Held on June 28, 2021
June 15, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences
May 27, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
Bicycle Therapeutics Announces Presentations at the AACR Annual Meeting 2021
April 10, 2021
From
Bicycle Therapeutics plc
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.